Digital therapeutic device startup ODIEN (CEO Sang-yeol Lee) announced that it has signed a three-party business agreement (MOU) with Kyung Hee University Medical Research Institute (President Kyung-sik Yoon) and clinical trial specialist DreamCIS (CEO Jeong-hee Yoo) for the joint development of next-generation obesity and diabetes treatments and digital healthcare solutions.
The signing ceremony was attended by ODIEN CEO Lee Sang-yeol (Professor of Endocrinology at Kyung Hee University Hospital), Kyung Hee Medical Research Institute Director Yoon Kyung-sik, and Dream CIS CEO Yoo Jeong-hee.
Through this agreement, the three organizations will collaborate in various areas, including ▲establishing and implementing clinical strategies for the development of next-generation obesity and diabetes treatments, ▲developing efficacy evaluation protocols for patients with severe obesity and data collection and monitoring, ▲developing and licensing continuous glucose monitoring devices, and ▲verifying a platform for chronic disease management of obesity and diabetes using digital therapeutic devices. ODN will be responsible for planning AI-based customized digital therapeutic devices and developing the platform, and will play a key role in data analysis and algorithm design for each patient condition.
“Based on our experience in the medical field and AI technology, we will implement customized treatment solutions for patients with severe obesity and diabetes,” said Lee Sang-yeol, CEO of ODIEN. “Through this collaboration, we will secure scientific evidence and increase the possibility of commercialization, thereby contributing to the improvement of national health.”
- See more related articles
You must be logged in to post a comment.